Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuronal acetylcholine receptor subunit alpha 4 plays a role in fast signal transmission at synapses. The Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline drugs market research report outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects.
CHRNA4 Pipeline Drugs Market by Key Therapy Areas
The key therapy area in the CHRNA4 pipeline drugs market is central nervous system.
Key Mechanism of Actions in the CHRNA4 Pipeline Drugs Market
The key mechanism of actions in the CHRNA4 pipeline drugs market are Neuronal Acetylcholine Receptor Subunit Alpha 4 Agonist and Neuronal Acetylcholine Receptor Subunit Alpha 4 Antagonist.
CHRNA4 Pipeline Drugs Market, by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the CHRNA4 Pipeline Drugs Market
The key route of administration in the CHRNA4 pipeline drugs market is oral.
Key Molecule Types in the CHRNA4 Pipeline Drugs Market
The key molecule type in the CHRNA4 pipeline drugs market is small molecule.
Key Companies in the CHRNA4 Pipeline Drugs Market
The key companies in the CHRNA4 pipeline drugs market are Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd.
Neuronal Acetylcholine Receptor Subunit Alpha 4 Pipeline Drugs Market Report Overview
Key Therapy Areas | Central Nervous System |
Key Mechanism of Actions | Neuronal Acetylcholine Receptor Subunit Alpha 4 Agonist and Neuronal Acetylcholine Receptor Subunit Alpha 4 Antagonist |
Key Routes of Administration | Oral |
Key Molecule Types | Small Molecule |
Key Companies | Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4).
- Reviews of targeted therapeutics for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) therapeutics and enlists all their major and minor projects.
- Assessment of Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the CHRNA4 pipeline drugs market?
The key therapy area in the CHRNA4 pipeline drugs market is central nervous system.
-
What are the key mechanism of actions in the CHRNA4 pipeline drugs market?
The key mechanism of actions in the CHRNA4 pipeline drugs market are Neuronal Acetylcholine Receptor Subunit Alpha 4 Agonist and Neuronal Acetylcholine Receptor Subunit Alpha 4 Antagonist.
-
What are the key routes of administration in the CHRNA4 pipeline drugs market?
The route of administration in the CHRNA4 pipeline drugs market is oral.
-
What are the key molecule types in the CHRNA4 pipeline drugs market?
The key molecule type in the CHRNA4 pipeline drugs market is small molecule.
-
Which are the key companies in the CHRNA4 pipeline drugs market?
The key companies in the CHRNA4 pipeline drugs market are Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.